Alfresa Holdings Corporation (ALFRY) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cotizando a $, Alfresa Holdings Corporation (ALFRY) es una empresa del sector Healthcare valorada en 0. Calificado con 49/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 16 mar 2026Alfresa Holdings Corporation (ALFRY) Resumen de Asistencia Médica y Tuberías
Alfresa Holdings Corporation, a Japanese healthcare conglomerate, manufactures, wholesales, and distributes pharmaceuticals, diagnostic reagents, and medical devices. With a focus on ethical pharmaceuticals and self-medication products, the company serves hospitals, clinics, and pharmacies in Japan and internationally, maintaining a stable position in the medical distribution landscape.
Tesis de Inversión
Alfresa Holdings Corporation presents a stable investment profile within the healthcare distribution sector. The company's diversified revenue streams, spanning ethical pharmaceuticals, self-medication products, and manufacturing, provide resilience against market fluctuations. With a P/E ratio of 12.91 and a dividend yield of 2.76% as of 2026-03-16, Alfresa offers a blend of value and income potential. The company's low beta of -0.16 suggests a lower sensitivity to market volatility compared to its peers. Growth catalysts include expanding its self-medication product lines and penetrating new international markets. Potential risks include regulatory changes in the pharmaceutical industry and increased competition from other distributors.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market capitalization of $2.91 billion indicates a substantial presence in the healthcare sector.
- P/E ratio of 12.91 suggests a reasonable valuation compared to earnings.
- Dividend yield of 2.76% provides a steady income stream for investors.
- Gross margin of 7.1% reflects the company's ability to manage its cost of goods sold.
- Profit margin of 1.1% indicates areas for potential improvement in operational efficiency.
Competidores y Pares
Fortalezas
- Diversified revenue streams across wholesale, manufacturing, and pharmacy operations.
- Established distribution network in Japan.
- Strong relationships with key customers, including hospitals and pharmacies.
- Manufacturing capabilities for active pharmaceutical ingredients and finished drugs.
Debilidades
- Relatively low profit margin compared to industry peers.
- Dependence on the Japanese market.
- Exposure to regulatory changes in the pharmaceutical industry.
- Limited international presence compared to global competitors.
Catalizadores
- Ongoing: Expansion of self-medication product lines to meet growing consumer demand for OTC drugs and health supplements.
- Ongoing: Strategic partnerships to enhance distribution network and market reach in key regions.
- Upcoming: Potential regulatory approvals for new pharmaceutical products, expanding the company's product portfolio.
- Ongoing: Investment in digital distribution channels to capitalize on the growth of e-pharmacy market.
- Ongoing: Development of value-added services to enhance customer loyalty and generate recurring revenue.
Riesgos
- Potential: Increased competition from other pharmaceutical distributors, leading to pricing pressures.
- Potential: Changes in government regulations and healthcare policies, affecting reimbursement rates and market access.
- Potential: Economic downturns affecting healthcare spending and consumer demand for pharmaceuticals.
- Ongoing: Currency fluctuations between the U.S. dollar and the Japanese yen, impacting the value of the ADR.
- Potential: Product liability claims or recalls, damaging the company's reputation and financial performance.
Oportunidades de crecimiento
- Expanding Self-Medication Product Lines: Alfresa can capitalize on the growing demand for over-the-counter drugs and health supplements. The global self-medication market is projected to reach $200 billion by 2028. By introducing innovative products and expanding its distribution network, Alfresa can increase its market share in this segment. Timeline: Ongoing.
- Penetrating New International Markets: Alfresa has the opportunity to expand its presence in emerging markets with growing healthcare needs. The Asia-Pacific region, in particular, offers significant growth potential. By establishing partnerships and adapting its product offerings to local market demands, Alfresa can diversify its revenue streams. Timeline: 2-3 years.
- Enhancing Contract Manufacturing Services: Alfresa can leverage its manufacturing capabilities to offer contract manufacturing services to other pharmaceutical companies. The global pharmaceutical contract manufacturing market is expected to reach $150 billion by 2027. By investing in advanced manufacturing technologies and expanding its capacity, Alfresa can attract new clients and generate additional revenue. Timeline: Ongoing.
- Strengthening Digital Distribution Channels: Alfresa can enhance its online presence and develop digital distribution channels to reach a wider customer base. The e-pharmacy market is experiencing rapid growth, driven by increasing internet penetration and changing consumer preferences. By investing in e-commerce platforms and digital marketing strategies, Alfresa can capture a share of this growing market. Timeline: 1-2 years.
- Developing Value-Added Services: Alfresa can differentiate itself from competitors by offering value-added services to its customers, such as inventory management, supply chain optimization, and data analytics. These services can help hospitals, clinics, and pharmacies improve their operational efficiency and reduce costs. By providing customized solutions and building strong customer relationships, Alfresa can enhance customer loyalty and generate recurring revenue. Timeline: Ongoing.
Oportunidades
- Expanding self-medication product lines to capitalize on growing consumer demand.
- Penetrating new international markets, particularly in Asia-Pacific.
- Enhancing contract manufacturing services to generate additional revenue.
- Strengthening digital distribution channels to reach a wider customer base.
Amenazas
- Increased competition from other pharmaceutical distributors.
- Pricing pressures from generic drugs.
- Changes in government regulations and healthcare policies.
- Economic downturns affecting healthcare spending.
Ventajas competitivas
- Established distribution network in Japan.
- Diversified product portfolio spanning pharmaceuticals, diagnostics, and medical devices.
- Manufacturing capabilities for active pharmaceutical ingredients and finished drugs.
- Strong relationships with hospitals, clinics, and pharmacies.
Acerca de ALFRY
Incorporated in 2003 and based in Tokyo, Japan, Alfresa Holdings Corporation has established itself as a key player in the healthcare sector. The company operates through its subsidiaries, engaging in the manufacture, wholesale, marketing, and import/export of a diverse range of healthcare products. These include pharmaceuticals, diagnostic reagents, and medical devices/equipment. Alfresa's operations are segmented into ethical pharmaceuticals wholesaling, self-medication products wholesaling, and manufacturing. The ethical pharmaceuticals division supplies hospitals, clinics, and dispensing pharmacies with essential products. The self-medication division caters to drug stores and pharmacies, offering over-the-counter drugs, health foods, and supplements. Alfresa also manufactures active pharmaceutical ingredients, pharmaceuticals, diagnostic reagents, and medical devices, providing contract manufacturing services. The company's medical-related business encompasses dispensing pharmacies and other healthcare activities, further solidifying its presence in the healthcare value chain. Alfresa's international reach extends its market presence beyond Japan, contributing to its revenue streams and overall growth.
Qué hacen
- Wholesales ethical pharmaceuticals to hospitals, clinics, and dispensing pharmacies.
- Distributes self-medication products, including OTC drugs and health supplements, to drug stores and pharmacies.
- Manufactures active pharmaceutical ingredients and pharmaceuticals.
- Produces diagnostic reagents and medical devices.
- Offers contract manufacturing services for pharmaceuticals.
- Operates dispensing pharmacies.
Modelo de Negocio
- Revenue from wholesale distribution of pharmaceuticals and medical products.
- Income from manufacturing and sales of active pharmaceutical ingredients and finished drugs.
- Fees from contract manufacturing services.
- Revenue generated from operation of dispensing pharmacies.
Contexto de la Industria
Alfresa Holdings Corporation operates within the medical distribution industry, a sector characterized by steady growth driven by aging populations and increasing healthcare expenditure. The industry is competitive, with players like CHSYF, DMPHF, HAWPF, HTSUF, and MAHLY vying for market share. Trends include consolidation among distributors and increased focus on supply chain efficiency. Alfresa's diversified product portfolio and established distribution network position it favorably within this landscape.
Clientes Clave
- Hospitals and clinics.
- Dispensing pharmacies.
- Drug stores.
- Other pharmaceutical companies (for contract manufacturing).
Finanzas
Gráfico e información
Precio de la acción de Alfresa Holdings Corporation (ALFRY): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para ALFRY.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para ALFRY.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para ALFRY.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de ALFRY en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Ryuji Arakawa
Unknown
Information regarding Ryuji Arakawa's specific background and career history is not available in the provided data. However, as the managing leader of Alfresa Holdings Corporation's 12,517 employees, Arakawa likely possesses extensive experience in the pharmaceutical or healthcare distribution industry. Further research would be needed to ascertain specific details about his education, previous roles, and credentials.
Historial: Due to the limited information available, Ryuji Arakawa's specific achievements and strategic decisions as CEO of Alfresa Holdings Corporation cannot be detailed. Evaluating his track record would require access to company performance data, strategic initiatives, and key milestones achieved under his leadership.
Información de ADR de Alfresa Holdings Corporation No patrocinado
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that trades on U.S. stock exchanges. ALFRY is an ADR representing shares of Alfresa Holdings Corporation, allowing U.S. investors to invest in the Japanese company without directly dealing with foreign exchanges. The ADR is denominated in U.S. dollars, simplifying trading and investment for U.S. investors.
- Ticker del mercado local: Tokyo Stock Exchange, Japan
- Nivel de ADR: 1
- Ratio de ADR: 1:1
- Ticker del mercado local: ALFR
Información del mercado OTC de ALFRY
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited financial disclosure and may not meet the listing requirements of major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries higher risks due to the lack of regulatory oversight and potential for fraud or manipulation. These companies are not required to be SEC reporting.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure increases the risk of investing in ALFRY.
- Low trading volume and wide bid-ask spreads can lead to price volatility and illiquidity.
- Lack of regulatory oversight increases the risk of fraud or manipulation.
- Potential for delisting or suspension of trading.
- Difficulty obtaining accurate and timely information about the company.
- Verify the company's registration and legal status.
- Obtain and review any available financial statements.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's risk factors and potential liabilities.
- Consult with a qualified financial advisor.
- Understand the OTC market and its associated risks.
- The company is an established player in the healthcare sector.
- Alfresa Holdings Corporation is based in Japan, a country with strong corporate governance standards.
- The company has a long operating history.
- ALFRY is an ADR, suggesting some level of scrutiny and compliance.
- The company has a market capitalization of $2.91 billion, indicating a substantial business.
ALFRY Preguntas Frecuentes sobre Acciones de Healthcare
¿Cuáles son los factores clave para evaluar ALFRY?
Alfresa Holdings Corporation (ALFRY) actualmente tiene una puntuación IA de 49/100, indicando puntuación baja. Fortaleza clave: Diversified revenue streams across wholesale, manufacturing, and pharmacy operations.. Riesgo principal a monitorear: Potential: Increased competition from other pharmaceutical distributors, leading to pricing pressures.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de ALFRY?
ALFRY actualmente puntúa 49/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de ALFRY?
Los precios de ALFRY se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre ALFRY?
La cobertura de analistas para ALFRY incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en ALFRY?
Las categorías de riesgo para ALFRY incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Increased competition from other pharmaceutical distributors, leading to pricing pressures.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de ALFRY?
La relación P/E para ALFRY compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está ALFRY sobrevalorada o infravalorada?
Determinar si Alfresa Holdings Corporation (ALFRY) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de ALFRY?
Alfresa Holdings Corporation (ALFRY) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available data as of 2026-03-16.
- Analyst consensus and detailed CEO background information are limited.
- OTC market data may be less reliable than exchange-listed data.